针灸联合SSRI治疗中重度抑郁:一项实用性随机对照试验的次要结局
本研究为实用性平行随机对照试验,纳入477例中重度抑郁患者,比较手针联合SSRI、电针联合SSRI与单用SSRI的疗效。结果显示,手针联合SSRI在迟缓因子优于单用SSRI,电针联合SSRI在焦虑/躯体化因子、睡眠障碍因子及生活质量多个领域优于单用SSRI。结论认为两种针灸联合SSRI均可改善症状和生活质量,但缺乏假针刺对照。
要点
- 手针联合SSRI可改善抑郁迟缓因子(第6周,p=0.008)。
- 电针联合SSRI可改善焦虑/躯体化因子(p<0.001)和睡眠障碍因子(p=0.002)。
- 电针联合SSRI在总体生活质量、一般健康、生理健康、心理健康优于单用SSRI(p<0.05)。
核心结论
- 手针或电针联合SSRI治疗均可改善中重度抑郁患者的症状和生活质量。
- 手针联合SSRI在迟缓因子优于单用SSRI,电针联合SSRI在焦虑/躯体化因子和睡眠障碍因子优于单用SSRI。
- 电针联合SSRI在生活质量多个领域优于单用SSRI,手针联合SSRI仅在心理健康领域有优势。
研究设计与样本
- 实用性、平行、随机对照试验,在中国6家医院开展。
- 477例患者随机分为手针联合SSRI组(n=161)、电针联合SSRI组(n=160)和单用SSRI组(n=156)。
- 干预6周,主要结局为第6周HAMD-17总分应答率,本分析报告次要结局。
主要发现
- 第6周HAMD-17迟缓因子:手针联合SSRI组显著优于单用SSRI组(p=0.008)。
- 第6周HAMD-17焦虑/躯体化因子(p<0.001)和睡眠障碍因子(p=0.002):电针联合SSRI组显著优于单用SSRI组。
- 第6周WHOQOL-BREF:电针联合SSRI组在总体生活质量、一般健康、生理健康、心理健康均较单用SSRI组显著改善(p<0.05)。
- 第6周WHOQOL-BREF心理健康领域:手针联合SSRI组较单用SSRI组显著改善(p=0.023)。
关键数值与推荐
- 手针联合SSRI组与单用SSRI组比较,第6周HAMD-17迟缓因子p=0.008。
- 电针联合SSRI组与单用SSRI组比较,第6周HAMD-17焦虑/躯体化因子p<0.001,睡眠障碍因子p=0.002。
- 电针联合SSRI组与单用SSRI组比较,第6周WHOQOL-BREF总体生活质量、一般健康、生理健康、心理健康p<0.05。
- 手针联合SSRI组与单用SSRI组比较,第6周WHOQOL-BREF心理健康p=0.023。
临床怎么用
- 对中重度抑郁患者,可考虑在手针或电针联合SSRI方案中根据症状特点选择:迟缓症状突出选手针,焦虑/躯体化或睡眠障碍突出选电针。
- 电针联合SSRI可能对总体生活质量、一般健康、生理健康和心理健康有更广泛获益。
- 手针联合SSRI可能对心理健康领域有改善作用。
局限性
- 本试验未使用假针刺对照,因此不能排除安慰剂效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore the effects of acupuncture (manual acupuncture or electroacupuncture) combined with SSRIs for moderate to severe depression improving major clinical symptoms and life quality of the patients on secondary outcomes. DESIGN: Pragmatic, parallel, randomized controlled trial. SETTING: 6 hospitals in China. INTERVENTIONS: 6 weeks of manual acupuncture (MA)+selective serotonin reuptake inhibitors (SSRIs), electroacupuncture (EA)+SSRIs, and SSRIs alone. MAIN OUTCOME MEASURES: The primary outcome was response rate of 17-item Hamilton Depression Scale (HAMD-17) total score at 6th week. The secondary outcomes reported in this analysis were HAMD-17 factor scores at 1st, 2nd, 4th, 6th, 10th week and WHO Quality of Life-BREF (WHOQOL-BREF) scores at 6th week. RESULTS: 477 patients were randomly assigned into MA + SSRIs (n = 161), EA + SSRIs (n = 160), or SSRIs alone (n = 156) groups. For HAMD-17 (at 6th week), the MA + SSRIs group was significantly better than the SSRIs alone group in retardation factor (p = 0.008), while the EA+SSRIs group was significantly better than the SSRIs alone group in anxiety/somatization factor (p<0.001) and sleep disturbance factor (p = 0.002). For WHOQOL-BREF (at 6th week), the EA + SSRIs group, compared with the SSRIs alone group, produced a more significant improvement in the overall quality of life, general health, physical health, and psychological health (p<0.05). While, the MA + SSRIs group, compared to the SSRIs alone group, showed significant advantage only in psychological health (p = 0.023). CONCLUSIONS: Either MA or EA combined SSRIs treatment could improve symptoms and quality of life for patients with moderate to severe depression. The main limitation of this trial was not using a sham control therefore the placebo effect could not be excluded.
引用
- Zhao B, Li Z, Wang Y, et al. Can acupuncture combined with SSRIs improve clinical symptoms and quality of life in patients with depression? Secondary outcomes of a pragmatic randomized controlled trial. Complement Ther Med. 2019. PMID: 31331577. doi:10.1016/j.ctim.2019.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。